STOCK TITAN

Astria Therapeutics Inc - ATXS STOCK NEWS

Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.

Astria Therapeutics Inc (ATXS) is a biopharmaceutical innovator developing monoclonal antibody therapies for rare immunological conditions like hereditary angioedema and atopic dermatitis. This page aggregates all official company announcements and verified news updates for stakeholders tracking its preclinical pipeline and scientific advancements.

Investors and researchers will find timely updates on clinical developments, regulatory milestones, and strategic partnerships. Our curated feed includes progress reports on key candidates like plasma kallikrein inhibitors and OX40 antagonists, along with analyses of their potential impact on underserved patient populations.

Content spans trial design announcements, patent filings, executive commentary, and peer-reviewed research collaborations. All materials are vetted for accuracy and presented in chronological order to help users track the company's evolving position in the rare disease therapeutics market.

Bookmark this page for streamlined access to ATXS's latest scientific disclosures and corporate developments. Check regularly for updates on antibody engineering breakthroughs and preclinical validation studies shaping the future of immune disorder treatments.

Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ: ATXS) announced on April 1, 2022, the grant of equity awards under its 2022 Inducement Stock Incentive Plan. The awards, totaling options for 32,500 shares of common stock, were given to new employees as an incentive. Each option has an exercise price of $6.48, matching the closing stock price on the grant date. The options will vest over four years, contingent upon the employees' continued employment. Astria focuses on developing therapies for rare allergic and immunological diseases, with its lead program being STAR-0215 for hereditary angioedema.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) reported its financial results for Q4 and full year 2021, alongside updates on its STAR-0215 therapy for hereditary angioedema (HAE). The company plans to file an IND application for STAR-0215 mid-year and initiate a Phase 1a clinical trial with initial results expected by year-end. As of December 31, 2021, cash and equivalents totaled $125.5 million. The net loss for 2021 was $194.9 million, significantly impacted by a $164.6 million in-process R&D expense from acquiring Quellis Biosciences.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.44%
Tags
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced participation in two investor conferences. The company will present on March 17, 2022, at Oppenheimer’s 32nd Annual Healthcare Conference, featuring CEO Jill C. Milne discussing their lead program STAR-0215 for hereditary angioedema. Additionally, Astria will be involved in the Guggenheim Healthcare Talks on March 31 and April 1, 2022. A live webcast of the Oppenheimer presentation will be available, with an archive accessible for 30 days post-event. Astria Therapeutics is focused on developing therapies for rare allergic and immunological diseases.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.68%
Tags
conferences
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) announced it will present new preclinical data for its drug candidate STAR-0215 at the AAAAI Annual Scientific Meeting in Phoenix, Arizona, on February 28, 2022. STAR-0215 is a long-acting monoclonal antibody designed to treat hereditary angioedema (HAE) by inhibiting plasma kallikrein, with a dosing schedule of once every three months or longer. After filing an IND application mid-2022, Astria plans to initiate a Phase 1 trial with initial results expected by year-end.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.88%
Tags
conferences
-
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) reported Q3 2021 financial results and company updates, highlighting the development of STAR-0215 for hereditary angioedema (HAE). The company aims to reduce patient treatment burden with less frequent dosing. They expect initial Phase 1 clinical trial results by year-end 2022. As of September 30, 2021, Astria had $131.8 million in cash, sufficient to finance operations through 2023. Q3 net loss improved to $7.9 million, down from $10.9 million in Q3 2020, with a net loss per share of $0.61.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.86%
Tags
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical firm, announced that CEO Jill C. Milne, Ph.D., will present information on their lead program STAR-0215 at the Jefferies London Healthcare Conference. The presentation will be available on-demand from November 18, 3:00 am ET to November 19, 12:00 pm ET. Attendees can access the webcast via the Investors section of Astria's website and at this link. An archived replay will be available for 30 days following the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.04%
Tags
conferences
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) presented new preclinical data for STAR-0215, a monoclonal antibody targeting hereditary angioedema (HAE), showing it binds to plasma kallikrein with ten-fold greater potency than lanadelumab. The study revealed STAR-0215's extended plasma half-life of about 34 days, allowing for potential dosing every three months. This profile supports its aim to be a patient-friendly treatment option. The company plans to file an Investigational New Drug application for STAR-0215 in mid-2022, with initial Phase 1 trial results expected by year-end 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.74%
Tags
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) is set to release its third quarter 2021 financial results on November 10, 2021, before the market opens. The CEO, Jill C. Milne, will host a conference call at 8:30 am ET to discuss the results and ongoing corporate developments. Known for its lead program STAR-0215, which targets hereditary angioedema, Astria aims to provide innovative therapies for rare immunological diseases. Investors can participate via a toll-free dial-in number or by accessing a live webcast on the company's website.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.58%
Tags
conferences earnings
-
Rhea-AI Summary

Astria Therapeutics, Inc. (NASDAQ:ATXS) announced new preclinical results for its lead program, STAR-0215, aimed at treating hereditary angioedema (HAE). These results will be presented at the 2021 American College of Allergy, Asthma and Immunology Annual Scientific Meeting in New Orleans on November 5, 2021, by Chief Scientific Officer Andrew Nichols. STAR-0215 is a monoclonal antibody plasma kallikrein inhibitor still in preclinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.55%
Tags
conferences clinical trial
Rhea-AI Summary

Astria Therapeutics (NASDAQ:ATXS) presented significant findings at the 2021 NORD Rare Diseases and Orphan Products Breakthrough Summit, highlighting a substantial need to alleviate both the disease and treatment burden for hereditary angioedema (HAE) patients. Interviews with ten HAE patients revealed that they desire therapies with similar efficacy but less frequent dosing. The company aims to address these needs through its preclinical program, STAR-0215, which could offer a patient-friendly option with dosing every three months or longer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.54%
Tags
none
Astria Therapeutics Inc

Nasdaq:ATXS

ATXS Rankings

ATXS Stock Data

231.94M
49.58M
0.47%
104.71%
5.64%
Biotechnology
Pharmaceutical Preparations
Link
United States
BOSTON